A Case of Hageman-Factor Deficiency and a Method to Purify the Factor

Summary

1. Description of a new case of Hageman factor deficiency. The patient’s plasma was used for a quantitative estimation of the Hageman factor in normal plasma.

2. By means of adsorption on to glass and elution at pH 9.6 followed by salting out procedures, it was possible to obtain a concentrated HF preparation, free from any other known coagulation factors.

3. There were strong indications for the assumption that the activation of HF does not take place by releasing any inhibitor. It could result from a dissociation by the glass surface of a less active protein into two or more active factors.

4. The slight inhibition which HF deficient plasma exerts on the activation of normal plasma is possibly caused by the occupation of the glass surface by non-specific proteins from HF deficient plasma.

5. In plasma HF is reversibly bound to other non-specific proteins in the ß and y globulin fraction.

6. After the activation by a glass surface the HF is still active in siliconed glass-ware.

• References

• Bachmann F, Duckert F, Koller F. The Stuart-Prower Factor Assay and its clinical Significance. Thromb. Diath. haem. 02: 24 1958;
• Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path. 06: 23 1953;
• Biggs R, Macfarlane R. G. Fluman Blood Coagulation. 2nd Edition.. Blackwell; Oxford: 1957
• Brinkhous K. M, Wagner R. H. Antihemophilic factor (A,H.F.); Some aspects of its biochemistry. 4th International Congress of Biochemistry, Vienna 1958. Symposion X: blood clotting factors. Pergamon Press Ltd; 1959
• Caen J, Bernard J. Deficit en facteur Hageman. Rev. Hémat. 13: 154 1958;
• Hardisty R. M, Margolis J. The role of Flageman factor in the initiation of blood coagulation. Brit. J. Haemat. 05: 203 1959;
• Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VII). Acta haemat. (Basel) 06: 1 1951;
• Macfarlane R. G. A simple method for measuring clot retraction. Lancet I. 1199 1939;
• Marbet R, Winterstein A. Der Heparin-Toleranztest. Ärztl. Forsch. 09: 460 1955;
• Margolis J. Glass surface and blood coagulation. Nature 178: 805 1956;
• Narasinga M. SRao, Kegeler G. An ultracentrifuge study of the polymerization of x-chyomtrypsin. J. Amer. chem. Soc. 80: 5724 1958;
• Ovren P. A, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 03: 201 1951;
• Ratnoff O. D. A familial trait characterized by deficiency of a clot-promoting fraction of plasma. J. Lab. clin. Med. 44: 915 1954;
• Ratnoff O. D, Rosenblum J. M. Role of Hageman factor in the initiation of clotting by glass. Amer. J. Med. 25: 160 1958;
• Soulier J. P, Larrieu M. J. Deficit en 3ème facteur prothromboplastique plasmatique. Rapports entrele P.T.A. etlefacteur Hageman. Thromb. Diath. haem. 02: 1 1958;
• Soulier J. P, Wartelle O, Ménaché D. Hageman trait and P.T.A. deficiency. Brit. J. Haemat. 05: 121 1959;